Table 4.
Heparin administration in the interventional and observational cohort
| Interventional cohort | Observational cohort | P-value | |||
|---|---|---|---|---|---|
| N | Median (IQR) or n (%) | N | Median (IQR) or n (%) | ||
| Pre-enrolment heparin administration | 98 | 66 (66.0%) | n/a | n/a | |
| Dose | 64 | n/a | n/a | ||
| 40 mg | 45 (70.3%) | ||||
| 60 mg | 10 (15.6%) | ||||
| 80 mg | 8 (12.5%) | ||||
| 100 mg | 1 (1.6%) | ||||
| Heparin dosage | 98 | 203 | < 0.001 | ||
| 40 mg | 0 (0.0%) | 198 (97.5%) | |||
| 60 mg | 6 (6.1%) | 2 (1.0%) | |||
| 80 mg | 81 (82.7%) | 3 (1.5%) | |||
| 100 mg | 11 (11.2%) | 0 (0.0%) | |||
| Day 3 Anti Xa activity (IU/mL) | 69 | 0.58 (0.48, 0.66) | n/a | n/a | |
| Day 5 Anti Xa activity (IU/mL) | 63 | 0.58 (0.47, 0.65) | n/a | n/a | |
| Heparin new dosage [mg] | 30 | n/a | n/a | ||
| 40 mg | 3 (10.0%) | ||||
| 60 mg | 19 (63.3%) | ||||
| 80 mg | 4 (13.3%) | ||||
| 100 mg | 4 (13.3%) | ||||